Business Context and Reporting Period
This Form 8-K Current Report from Sight Sciences, Inc. (SGHT) covers the period ending March 27, 2026. The filing primarily addresses a significant legal development regarding patent infringement litigation against Alcon Inc. and related entities concerning the Hydrus Microstent.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the litigation outcome:
- Monetary Damages Awarded: $34 million for past infringement.
- Ongoing Royalty: 10% of Hydrus revenue through November 10, 2028.
- Supplemental Damages and Interest: To be calculated prior to the entry of a Final Judgment.
Material Changes and Legal Developments
On March 27, 2026, the U.S. District Court for the District of Delaware issued an order preserving a jury verdict of willful infringement by Alcon against Sight Sciences. This order confirms:
- Alcon willfully infringed three Sight Sciences patents (U.S. Patent Nos. 8,287,482; 9,370,443; and 11,389,328).
- The award of $34 million in damages plus an ongoing 10% royalty on Hydrus revenue.
- A Final Judgment is expected in the coming months but is subject to appeal by Alcon.
Outlook, Risks, and Contingencies
Management highlights several critical contingencies and risks that may impact the realization of the awarded damages:
- Appeal Process: No monetary damages will be recovered until Alcon exhausts its appeal rights or the appeal period expires.
- Patent Validity Challenges: In June 2025, Alcon filed petitions for ex parte reexamination (EPR) with the USPTO challenging the validity of the asserted patents. Adverse final rulings on these EPRs could negatively affect the Company's ability to collect on the Final Judgment.
- Historical Context: Previous inter partes review petitions by Alcon were denied by the USPTO in March 2023.
Investor Verification Checklist
- Verify the status of Alcon's appeal of the March 27, 2026 court order.
- Monitor the progress and outcome of the USPTO ex parte reexamination (EPR) proceedings initiated in June 2025.
- Confirm the timeline for the calculation of supplemental damages and pre-judgment interest.
- Review the press release (Exhibit 99.1) for detailed terms of the ongoing royalty agreement.